|Short-Term Fasting: Impact on Toxicity
Basic Trial Information
Further Trial Information
Trial Contact Information
Basic Trial Information
|No phase specified||Supportive care||Active||Over 18||0S-08-9|
This partially randomized clinical trial studies short-term fasting in reducing side effects in patients receiving gemcitabine hydrochloride and cisplatin for advanced solid tumors. Short-term fasting before chemotherapy may reduce the side effects caused by chemotherapy. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Further Study Information
I. To determine the safety and feasibility of short-term fasting prior to administration of combination chemotherapy with platinum in patients with advanced solid tumor malignancies.
II. To evaluate the toxicity profile of platinum-based chemotherapy in subjects who eat normally compared to those who undertake short-term starvation.
III. To investigate changes in plasma insulin, glucose, IGF1 and IGF binding protein (IGFBP) levels, and oxidative stress markers in subjects who undertake short-term fasting compared to controls.
IV. To investigate whether changes in grp78 expression occur after fasting and after chemotherapy administration in human subjects.
STAGE I: Patients are assigned to 1 of 4 treatment groups. GROUP I: Patients fast for 24 hours on day-1.
GROUP II: Patients fast for 48 hours on days -2 and -1.
GROUP III: Patients fast for 72 hours on days -3, -2, and-1.
GROUP IV: Patients undergo a modified 48-hour fast with minimal caloric intake on days -2 and -1.
STAGE II: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients fast for 72 hours on days -2, and on day 1.
ARM II: Patients proceed to chemotherapy without fasting.
All patients receive gemcitabine hydrochloride intravenously (IV) on days 1 and 8 and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
- Histologically confirmed malignancy for which platinum-based chemotherapy on a 21 day cycle or 14 day cycle is being recommended.
- Stage I of the trial: newly diagnosed disease for which neoadjuvant or adjuvant chemotherapy is planned in the curative setting, or metastatic disease.
- Stage II of the trial: Measurable disease (metastatic) by RECIST criteria must be present for all subjects in the randomized component of the trial- if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy.
- Stage I: subjects may have already received no more than 2 cycle of platinum-based chemotherapy, but should not have received other prior chemotherapy regimens with the exception of patients with metastatic disease who received neoadjuvant or adjuvant chemotherapy and that chemotherapy was completed > 6 months prior to enrollment.
- Stage II: subjects must have received no prior chemotherapy regimens for metastatic disease, and no more than 1 cycle of their current platinum chemotherapy regimen for metastatic disease. They may have received prior neoadjuvant or adjuvant chemotherapy, provided such therapy was completed >6 months prior to enrollment.
- Prior Radiotherapy is allowed, provided at least 2 weeks have elapsed from completion of radiotherapy to initiation of protocol treatment.
- ECOG performance status 0-1
- Adequate renal function (Creatinine <1.25 ULIN or calculated creatinine clearance > 50 ml/min)
- Premenopausal women must have a negative pregnancy test and must agree to use barrier contraception throughout the study period.
- Recent significant or unexplained weight loss that the investigator feels may pose an unacceptable risk for enrollment. Candidates who are overweight and have lost weight intentionally via diet or exercise should not be excluded.
- Peripheral Neuropathy > grade 1
- History of significant cardiac disease, particularly uncompensated congestive heart failure NYHA grade 2 or more or LVEF < 40% on any prior assessment. (Assessment of LVEF prior to therapy is not required in the absence of other clinical indicators of heart disease). Patients with a prior LVEF <40% will require re-evaluation prior to study entry.
- Subjects on medications that may not be safely stopped during the fasting portion of the study, or which may not be safely consumed without food.
- A history of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous.
Trial Contact Information
Trial Lead Organizations/Sponsors
USC/Norris Comprehensive Cancer Center and Hospital
|Tanya Dorff, MD||Principal Investigator|
| ||USC/Norris Comprehensive Cancer Center and Hospital|
| ||Tanya Dorff, MD||
| ||Tanya Dorff, MD||Principal Investigator|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00936364
ClinicalTrials.gov processed this data on January 27, 2014
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.